Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2006 2
2007 1
2008 6
2009 11
2010 8
2011 5
2012 16
2013 15
2014 9
2015 10
2016 12
2017 13
2018 12
2019 8
2020 7
2021 7
2022 16
2023 16
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Results by year

Filters applied: . Clear all
Page 1
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horowitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Del Valle DM, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK. Galsky MD, et al. Among authors: yu m. Nat Med. 2023 Nov;29(11):2825-2834. doi: 10.1038/s41591-023-02568-1. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783966 Free PMC article. Clinical Trial.
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
Zhao SG, Sperger JM, Schehr JL, McKay RR, Emamekhoo H, Singh A, Schultz ZD, Bade RM, Stahlfeld CN, Gilsdorf CS, Hernandez CI, Wolfe SK, Mayberry RD, Krause HM, Bootsma M, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Kyriakopoulos CE, Kosoff D, Wei XX, Floberg J, Sethakorn N, Sharifi M, Harari PM, Huang W, Beltran H, Choueiri TK, Scher HI, Rathkopf DE, Halabi S, Armstrong AJ, Beebe DJ, Yu M, Sundling KE, Taplin ME, Lang JM. Zhao SG, et al. Among authors: yu m. J Clin Invest. 2022 Nov 1;132(21):e161858. doi: 10.1172/JCI161858. J Clin Invest. 2022. PMID: 36317634 Free PMC article.
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.
Aggarwal R, Rydzewski NR, Zhang L, Foye A, Kim W, Helzer KT, Bakhtiar H, Chang SL, Perry MD, Gleave M, Reiter RE, Huang J, Evans CP, Alumkal JJ, Lang JM, Yu M, Quigley DA, Sjöström M, Small EJ, Feng FY, Zhao SG. Aggarwal R, et al. Among authors: yu m. JAMA Oncol. 2021 Nov 1;7(11):1644-1652. doi: 10.1001/jamaoncol.2021.3987. JAMA Oncol. 2021. PMID: 34554200 Free PMC article.
Which test for crossing survival curves? A user's guideline.
Dormuth I, Liu T, Xu J, Yu M, Pauly M, Ditzhaus M. Dormuth I, et al. Among authors: yu m. BMC Med Res Methodol. 2022 Jan 30;22(1):34. doi: 10.1186/s12874-022-01520-0. BMC Med Res Methodol. 2022. PMID: 35094686 Free PMC article. Review.
Risk factors, pathophysiology, and treatment of hot flashes in cancer.
Fisher WI, Johnson AK, Elkins GR, Otte JL, Burns DS, Yu M, Carpenter JS. Fisher WI, et al. Among authors: yu m. CA Cancer J Clin. 2013 May;63(3):167-92. doi: 10.3322/caac.21171. Epub 2013 Jan 25. CA Cancer J Clin. 2013. PMID: 23355109 Free PMC article. Review.
157 results